Clinical trial
Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg…
NCT00059644 · Tanabe Pharma Corporation, Industry · Terminated
Key facts
| NCT number | NCT00059644 |
|---|---|
| Title | Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease |
| Official title | A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM for the Treatment of Critical Leg Ischemia |
| Lead sponsor | Tanabe Pharma Corporation, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Peripheral Vascular Disease |
| Intervention type | Drug |
| Interventions | Ecraprost in lipid emulsion |
| Enrollment | 560 |
| Start date | Jul 1, 2001 |
| Completion | Jun 1, 2004 |
| First posted | May 2, 2003 |
| Last update posted | Jun 24, 2005 |
| Countries | United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: